title: A pilot randomized study on use of oral acetazolamide in patients with refractory dysuria.
abstract: OBJECTIVE
  Assessment of daily oral acetazolamide in treatment of refractory dysuria.
  
  
  METHODS
  Forty-one patients were randomly allocated to either be treated with acetazolamide (250 mg twice daily) or to receive placebo. The irritative voiding symptoms and urinary pH were recorded before and after treatment. The quality of life indices including the impact of voiding symptoms on daily and social activities, mood disturbance and sleep disorders were also measured by a questionnaire.
  
  
  RESULTS
  Urinary pH was increased in the group taking acetazolamide (P < 0.001). They also reported alleviation of dysuria (P < 0.001), frequency (P = 0.039) and urgency (P = 0.016). However, nocturia was not improved in the study group. No change was observed in the aforementioned parameters in the placebo group. Daily personal life, social activities and the quality of sleep were improved by 52, 38 and 33%, respectively.
  
  
  CONCLUSIONS
  Oral acetazolamide can reduce the irritative voiding symptoms and improve the quality of life which is concomitant with an increase in urinary pH.
authors.affiliation: Department of Urology, Imam Reza Hospital, Aja University of Medical Sciences, Tehran, Islamic Republic of Iran. ahmadm90@me.com.
authors.forename: Morteza
authors.initials: M
authors.lastname: Hamidi
authors.affiliation: Department of Urology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
authors.forename: Seyed Mohammad Kazem
authors.initials: SMK
authors.lastname: Aghamir
authors.affiliation: Department of Urology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
authors.forename: Alborz
authors.initials: A
authors.lastname: Salavati
authors.affiliation: Department of Urology, Imam Reza Hospital, Aja University of Medical Sciences, Tehran, Islamic Republic of Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Masoomi
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage / Q000627:therapeutic use*; D000203:Activities of Daily Living; D000284:Administration, Oral; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D053159:Dysuria / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011788:Quality of Life; D012720:Severity of Illness Index; D012890:Sleep; D058992:Social Participation; D014554:Urination; D014556:Urine / Q000737:chemistry
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide
keywords: Acetazolamide; Quality of life; Refractory dysuria; Urine pH